You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Novel Cation-Exchange Wound Dressing for Diabetic Ulcers
SBC: AEGIS BIOSCIENCES, LLC Topic: N/ADESCRIPTION (provided by applicant): As many as 20 million people in the United States have diabetes and more than two million of these individuals will develop diabetic foot ulcers during their lifetime. In addition, the incidence of ulcer recurr
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Bifunctional T cell receptor based immunotherapeutics
SBC: Altor BioScience, LLC Topic: N/ADESCRIPTION (provided by applicant): The goal of these studies is to further pre-clinical development of a soluble three-domain single chain T-cell receptor IL-2 fusion protein (264scTCR/IL-2). This T-cell receptor, which recognizes an unmutated peptide epitope of the human tumor suppressor protein, p53, presented in the context of HLA-A2.1 is fully functional with respect to MHC restricted peptid ...
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Soluble T-cell receptor based tumor screening reagents
SBC: Altor BioScience, LLC Topic: N/ADESCRIPTION (provided by applicant): The goal of this research is to demonstrate proof-of-principle for using a T-cell receptor (TCR)-based fusion protein as a staining reagent for human tumors. The TCR portion of this fusion protein is specific for a
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
TRACHEAL GAS INSUFFLATION- PATIENT INTERFACE SYSTEM
SBC: ALVEOLI MEDICAL, LLC Topic: N/ADESCRIPTION (provided by applicant): The benefits of Tracheal Gas Insufflation (TGI) as an adjunct to mechanical ventilation are well known. 1 TGI reduces dead space and CO2 rebreathing in mechanically ventilated patients, thereby reducing PaCO2 with no c
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Indicator cells for antiviral screening for filoviruses
SBC: APATH, LLC Topic: N/ADESCRIPTION (provided by applicant): Filoviruses include some of the most notorious human pathogens and cause significant morbidity and mortality due to severe hemorrhagic fever syndromes. Unfortunately, very few therapeutic agents are available to treat
SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health -
Transgenic indicator cells for influenza virus
SBC: APATH, LLC Topic: N/ADESCRIPTION (provided by applicant): Influenza virus causes a pandemic disease of the respiratory tract that results in significant human morbidity and mortality. Diagnosis of influenza virus infection during the winter months makes up a large component
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Molecular tools for Bunyavirus antiviral screening
SBC: APATH, LLC Topic: N/ADESCRIPTION (provided by investigator): Several viruses in the family Bunyaviridae are significant human pathogens and potential agents of bioterrorism. Vaccines against some of these viruses do exist, but with the exception of ribavarin, there are no broad-spectrum antiviral compounds capable of inhibiting replication of more than one member of the family. Using LaCrosse virus (LAC) as a prototyp ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Replicon-based screening for inhibitors of alphaviruses
SBC: APATH, LLC Topic: N/ADESCRIPTION (provided by applicant): The goal in this study is to develop a cell-based assay to screen compounds for antiviral activity against certain members of the Togavirus family. We are particularly targeting the more pathogenic encephalitis-causing
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Production of human CD39 as an antithrombotic agent
SBC: APT THERAPEUTICS, INC. Topic: N/ADESCRIPTION (provided by applicant): Production of a human apyrase protein as an antithrombotic agent is proposed. Thrombotic vascular occlusion due to abnormal platelet aggregation can lead to many diseases, including ischemic stroke, myocardial infarcti
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Empower Math Project (EMP)
SBC: The Athena Group, Inc. Topic: N/AThe Phase I Empower Math Project (EMP) will result in a technology capable of delivering authentic, engaging, and relevant mathematics studies and understanding to a 9-12 grade audience. EMP is the result of fusing two existing complementary computer-based learning systems, developed by the proposer, called PenMATH and Lord Kelvin. By channeling student interests with authentic experiences, EMP ca ...
SBIR Phase I 2004 Department of Education